Loading patent…
AssigneesCase Western Reserve University, Invictus Therapeutics
InventorsMichael A. WEISS, Mentor MULAJ, Thomas HATTIER, Richard BERENSON, Laurie A. BROADWATER
Estimating the term…
A pharmaceutical composition comprises an effective amount of an insulin analogue comprising modified A-chain and B-chain polypeptides. The modified A chain comprises one or more substitutions relative to wild-type human insulin A-chain selected from a Gln, His or Glu substitution at position A8, a Glu or Ala substitution at position A14, and an Ala, Gln, Gly, or Thr substitution at position A21. The modified B-chain polypeptide comprises one or more modifications relative to wild-type human insulin B-chain selected from a deletion of the amino acid or amino acids at position B1, B1 and B2, or B1-B3, an Ala or Glu substitution at position B2, a Glu or Ala substitution at position B3, an Ala substitution at position B4; and a Glu or Lys substitution at position B29. The composition comprises one or more of iloprost, citrate, EDTA and a polyphosphate compound. The composition may be used to treat diabetes.
A pharmaceutical composition comprising an effective amount of an insulin analogue comprising a modified A-chain polypeptide and a modified B-chain polypeptide, wherein the modified A chain comprises one or more substitutions relative to the
The pharmaceutical composition of claim 39, wherein the composition further comprises magnesium.
A method for determining pharmacokinetic parameters of a formulation comprising an active pharmaceutical ingredient (API) comprising:
An insulin analogue comprising a modified A-chain polypeptide and a modified B-chain polypeptide,
Dependencies are inferred from the claim text.